Drug Trial Radar · NCT01295294
Management of Initial Bleeding/Spotting Associated With the Levonorgestrel-releasing Intrauterine System (MIRENA)
Last checked: Nov 20, 2026Latest source record: Nov 4, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
187
Actual
Start
Mar 2011
Primary completion
Dec 2011
Study completion Dec 2011
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Feb 14, 2011
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Single group
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is to investigate if the study drugs (tranexamic acid or mefenamic acid) can control irregular bleeding during the first 3 months of using Mirena. The study drugs tested are tested against placebo ("dummy medication not containing any active drug"). Treatment period is followed by a one-month period when study drugs are not taken but Mirena use is continued.
Conditions
- Uterine Hemorrhage
Interventions
Tranexamic acidDrug
500 mg 3 times daily per oral during bleeding/spotting episodes
Mefenamic acidDrug
500 mg 3 times daily per oral during bleeding/spotting episodes
PlaceboDrug
3 times daily per oral during bleeding/spotting episodes
Mirena (Levonorgestrel IUS, BAY86-5028)Drug
In vitro release rate 20 microgram/24 hours. Intrauterine system
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary efficacy variable will be the cumulative number of bleeding / spotting daysTime frame: During 90 day double-blind treatment period
Locations
12 sites in 3 countries. Site status is shown where the registry gives one.
Site not named
Aalborg, Denmark
Site not named
Århus C, Denmark
Site not named
København NV, Denmark
Site not named
Odense C, Denmark
Site not named
Skive, Denmark
Site not named
Søborg, Denmark
Site not named
Cork, Ireland
Site not named
Mallow, Cork, Ireland
Site not named
Blackrock, Dublin, Ireland
Site not named
Elverum, Norway
Site not named
Haugesund, Norway
Site not named
Trondheim, Norway
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.